FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
December 30, 2015 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Added to Russell 2000(R) Index
December 18, 2015 16:15 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO to Participate in Upcoming Investor and Scientific Conferences
December 01, 2015 09:11 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Dec. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Reports Third Quarter 2015 Results
November 05, 2015 08:02 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Nov. 5, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
Dr. David C. Stump Appointed to REGENXBIO Board of Directors
October 15, 2015 08:01 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Oct. 15, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board...
FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
October 01, 2015 17:05 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Oct. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (REGENXBIO) (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced that the U.S. Food and Drug Administration...
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 22, 2015 16:02 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of...
REGENXBIO Announces Pricing of Initial Public Offering
September 16, 2015 20:29 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of...
REGENXBIO Enters Into Strategic Manufacturing Collaboration With Wuxi Apptec
June 11, 2015 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md. and SHANGHAI, China, June 11, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into an exclusive strategic...
Dr. Jerry Karabelas Appointed to REGENXBIO Board of Directors
May 27, 2015 09:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., May 27, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the appointment of Jerry Karabelas, Ph.D., to its board of...